Synthetic Cannabinoid Abuse (Disorder)BonsaiNCT06235346
Ocular Effects of Synthetic Cannabinoids
An observational study of Synthetic Cannabinoid Abuse (Disorder) and Eye Manifestations, run by Bezmialem Vakif University at 1 site in Turkey (Türkiye).
Trial summary
The goal of this observational study is to evaluate the ocular effects of Bonzai (synthetic cannabinoids) with spectral-domain optical coherence tomography. Researchers will compare eye findings in patients who have previously used Bonzai with a healthy control group to see if there are ocular effects. Read more about this study
- Who is it for?
- Any age, men onlyHealthy volunteers can take part
- Conditions the study is for
- Synthetic Cannabinoid Abuse (Disorder), Eye Manifestations
- How many people
- 90 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 15 Mar 2015to 15 Jan 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Men only
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: The judiciary-supervised probation unit of Alcohol and Substance Research, Treatment and Training Centre (AMATEM) of Department of Psychiatry, Bakirkoy Training and Research Hospital for Psychiatry, Neurology and Neurosurgery, Istanbul, Turkey
Who may be able to join
- Male patients with past synthetic cannabinoids use and
- 30 eyes of age-matched 30 male healthy control subjects
Who cannot join
- present co-use of any substances other than synthetic cannabinoids
- chronic ocular disease, such as uveitis or glaucoma
- history of previous ocular surgery
- systemic disease, such as diabetes mellitus or hypertension
- systemic or topical drug use that may influence vascular tone, such as topical anti-glaucomatous and systemic anti-hypertensive medications
- refraction in spherical equivalent (SE) ± 1 dioptre (D) out of range. -
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Bakirkoy Dr. Sadi Konuk Educational and Research Hospital
Istanbul
About this study
Official title: Ocular Effects of Synthetic Cannabinoids: A Case-control Study
The goal of this observational study is to evaluate the ocular effects of Bonzai (synthetic cannabinoids) with spectral-domain optical coherence tomography.
Researchers will compare eye findings in patients who have previously used Bonzai with a healthy control group to see if there are ocular effects.
Read the detailed description
MATERIAL AND METHODS Participants This study was designed as cross-sectional, observational, case-control study. Upon referral from the judiciary-supervised probation unit of Alcohol and Substance Research, Treatment and Training Centre (AMATEM) of the relevant tertiary psychiatry hospital between March 2015 and January 2016, 60 eyes of 60 consecutive male patients with past synthetic cannabinoids (SC) use and 30 eyes of age-matched 30 male healthy control subjects were enrolled in the study in 3 groups: a control group (n=30) included eyes of subjects with no history of use of any substance including tobacco, a seronegative SC group (n=30) included eyes of patients declaring no present use of any substance, as verified by three consecutive negative urine toxicology tests performed two weeks apart, and a seropositive SC group (n=30), including eyes of patients with positive urine toxicology tests proving present use of SC.
SCs and relevant metabolites in urine samples were screened with a direct ELISA kit (K2 Enzyme Immunoassay, Immunalysis Corp., Pomona, CA, USA). This kit was able to detect relevant metabolites, such as JWH-018, JWH-073, and AM-2201, with a cut-off level of 20 ng/mL and over for positive results. Exposures to classical cannabinoids, ecstasy, amphetamines, opioids, and ethylene glycol were also screened.
Regarding SC use, the patients were asked about the duration and the last time of use. In addition, the previous use of other substances was questioned in detail.
Ophthalmic Assessments All eyes underwent ophthalmic examinations, including autorefraction, best-corrected visual acuity (BCVA) testing, biomicroscopy, non-contact IOP measurement, and dilated fundus examination.
An experienced technician performed spectral-domain optical coherence tomography (SD-OCT) imaging of all eyes following pupil dilatation (1% tropicamide) and systolic/diastolic blood pressure measurements (SBP/DBP). All SD-OCT assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation. Only high-quality SD-OCT images with a signal strength index (SSI) greater than 50 were sent for analysis. The parafoveal retinal thickness (parafoveal RT) and central foveal thickness (CFT), CT, peripapillary RNFL thickness, and macular GCC thickness measurements were performed with an RTVue-100 OCT device (Optovue Inc., Fremont, US), which had a 5 µm axial image resolution with a speed of 27,000 A-scans per second.
We preferred the ONH map protocol for examining the RNFL parameters. This protocol creates a RNFL thickness map based on measurements around a circle 3.45 mm in diameter centred on the ONH. The protocol for the GCC scan was based on examining a square grid (7 × 7 mm) on the central macula after centring 1 mm temporal to the macula. The average, superior, and inferior values displayed by the device were studied for the mean GCC and mean RNFL parameters.
Segmental divisions were recorded with the MM5 protocol of the inbuilt software, characterized by a 5 × 5 mm2 grid of 11 horizontal and 11 vertical lines with 668 A-scans and a 3 × 3 mm2 inner grid of 6 horizontal and 6 vertical lines with 400 A-scans for the retinal thickness of a 1 mm diameter CFT. The CT was measured by cross-sectioning through the foveolar centre line, characterized by an 8 mm width, with 1024 A-scans captured on the chorioretinal mode (these settings enable enhanced depth imaging along with contrast and brightness tuning). The line was rotated horizontally and vertically so that manual measurements were taken first at the central foveola and then 750 µm apart in the nasal, temporal, superior, and inferior directions with the ruler function, using a line extending from the posterior edge of the retinal pigment epithelium to the choroidoscleral junction.
The choroidal structure was analysed using the method previously described by Agrawal et al., and all collected images were processed and analysed using the open-source and publicly available ImageJ software (version 1.50a, freely available at http://imagej.nih.gov/ij/; National Institutes of Health [NIH], Bethesda, MD). According to this method, the image was first binarized using the Niblack auto-local thresholding function. This provided a clear visualization of the choroidoscleral interface while also enabling the precise selection of a region of interest, such as the total subfoveal choroidal area (TA). A fovea-centred, 1500 μm wide, nasal-to-temporal subfoveal choroidal area was manually selected using the polygon selection tool. The dark pixels representing the luminal area (LA) were selected using the colour threshold tool, and the residual light pixels were considered the stromal area (SA). The subfoveal CVI was calculated as the ratio of the LA to the TA. Manual measurements (CT and CVI) were carried out by the same experienced investigator blinded to the groups. Each measurement was repeated twice, and the mean of the two measurements was used in the analysis.
Statistical analysis Statistical analysis was conducted with software (SPSS 22.0 Version, IBM Corporation, New York, USA). Descriptive statistics were stated as the mean, standard deviation (SD), or median (Med), the interquartile range (Q1-Q3), and the frequency and ratio (%) values, where appropriate. The distribution of normality was evaluated for each parameter with the Kolmogorov-Smirnov test. Parametric (for normal distribution) or non-parametric tests were applied as appropriate. A parametric analysis of variance (ANOVA) with a post hoc Tukey test or a non-parametric Kruskal-Wallis test with a post hoc Bonferroni-corrected Mann-Whitney U test was used to analyse the independent variables. The chi-square test was used to analyse the qualitative data. Correlations of choroidal thickness measurements with parameters relevant to SC use were studied using the Spearman test.
- Keywords
- Bonzai, choroid, intraocular pressure, retina, synthetic cannabinoids
- Medical subject headings
- Eye Manifestations
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Control Group | Eyes of subjects with no history of use of any substance | |
| Seronegative Synthetic Cannabinoids Group | Eyes of patients declaring no present use of any substance and as verified by three consecutive negative urine toxicology tests performed two weeks apart | |
| Seropositive Synthetic Cannabinoids Group | Eyes of patients with positive urine toxicology tests proving present use of synthetic cannabinoids |
What is being measured
The primary outcome is the main question the study is designed to answer.
Intraocular pressure
Intraocular pressure measurement by non-contact air-puff tonometer. Intraocular pressure will be reported in mmHg
Measured: All assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.
Central foveal thickness
All measurements were obtained with the built-in software of the SD-OCT device. Central foveal thickness will be reported in µm.
Measured: All assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.
Peripapillary retinal nerve fibre layer thickness
All measurements were obtained with the built-in software of the SD-OCT device. Peripapillary retinal nerve fibre layer thickness will be reported in µm.
Measured: All assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.
Macular ganglion cell complex thickness
All measurements were obtained with the built-in software of the SD-OCT device. Macular Ganglion cell complex thickness will be reported in µm.
Measured: All assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.
Subfoveal and perifoveal choroidal thicknesses
Choroidal imaging carried out with Spectral domain optical coherence tomography by chorioretinal mode. All choroidal thicknesses were measured with the built-in caliper function. Subfoveal and perifoveal choroidal thicknesses will be reported in µm.
Measured: All SD-OCT assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.
Choroidal vascularity index
All choroidal images were exported to ImageJ software and binarized with Niblack autolocal thresholding method. After binarization, dark pixels indicate luminal area, and white pixels indicate stromal area. "Luminal area/total area(stromal+luminal area) * 100" formula will be used for choroidal vascularity index (CVI) calculation. CVI will be reported in %
Measured: All assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jan 2024
- Study start15 Mar 2015
- Primary completion15 Sep 2015
- Study completion15 Jan 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Synthetic Cannabinoid Abuse (Disorder)Studies of the same condition, open and under way.
- More trials run by Bezmialem Vakif UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bezmialem Vakif University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Ismail Umut Onur, MD, Study director, Bakirkoy Dr. Sadi Konuk Educational and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06235346
- Sponsor's protocol ID
- 2015/56
- Acronym
- Bonsai
- Status last verified
- Jan 2024
- First submitted
- 22 Jan 2024
- Last updated
- 31 Jan 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Agrawal R, Salman M, Tan KA, Karampelas M, Sim DA, Keane PA, Pavesio C. Choroidal Vascularity Index (CVI)--A Novel Optical Coherence Tomography Parameter for Monitoring Patients with Panuveitis? PLoS One. 2016 Jan 11;11(1):e0146344. doi: 10.1371/journal.pone.0146344. eCollection 2016.
PubMed 26751702Kunduraci MS, Kirik F, Onur IU, Onur OS, Karsidag C, Yigit FU, Erkiran M. Ocular effects of synthetic cannabinoids: a case-control study. Eye (Lond). 2025 Jan;39(1):94-101. doi: 10.1038/s41433-024-03381-x. Epub 2024 Oct 8.
PubMed 39375488
Study at a glance
From the registry record, last updated by the sponsor on 31 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ocular Effects of Synthetic Cannabinoids: A Case-control Study
- ClinicalTrials.gov ID
- NCT06235346
- Acronym / sponsor ID
- Bonsai / 2015/56
- Keywords
- Bonzai, choroid, intraocular pressure, retina, synthetic cannabinoids
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Bezmialem Vakif UniversityUniversity, hospital or other
- Study start
- 15 Mar 2015 (actual)
- Primary completion
- 15 Sep 2015 (actual)
- Study completion
- 15 Jan 2016 (actual)
- First posted
- 31 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to evaluate the ocular effects of Bonzai (synthetic cannabinoids) with spectral-domain optical coherence tomography.
Researchers will compare eye findings in patients who have previously used Bonzai with a healthy control group to see if there are ocular effects.
Detailed description
MATERIAL AND METHODS Participants This study was designed as cross-sectional, observational, case-control study. Upon referral from the judiciary-supervised probation unit of Alcohol and Substance Research, Treatment and Training Centre (AMATEM) of the relevant tertiary psychiatry hospital between March 2015 and January 2016, 60 eyes of 60 consecutive male patients with past synthetic cannabinoids (SC) use and 30 eyes of age-matched 30 male healthy control subjects were enrolled in the study in 3 groups: a control group (n=30) included eyes of subjects with no history of use of any substance including tobacco, a seronegative SC group (n=30) included eyes of patients declaring no present use of any substance, as verified by three consecutive negative urine toxicology tests performed two weeks apart, and a seropositive SC group (n=30), including eyes of patients with positive urine toxicology tests proving present use of SC.
SCs and relevant metabolites in urine samples were screened with a direct ELISA kit (K2 Enzyme Immunoassay, Immunalysis Corp., Pomona, CA, USA). This kit was able to detect relevant metabolites, such as JWH-018, JWH-073, and AM-2201, with a cut-off level of 20 ng/mL and over for positive results. Exposures to classical cannabinoids, ecstasy, amphetamines, opioids, and ethylene glycol were also screened.
Regarding SC use, the patients were asked about the duration and the last time of use. In addition, the previous use of other substances was questioned in detail.
Ophthalmic Assessments All eyes underwent ophthalmic examinations, including autorefraction, best-corrected visual acuity (BCVA) testing, biomicroscopy, non-contact IOP measurement, and dilated fundus examination.
An experienced technician performed spectral-domain optical coherence tomography (SD-OCT) imaging of all eyes following pupil dilatation (1% tropicamide) and systolic/diastolic blood pressure measurements (SBP/DBP). All SD-OCT assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation. Only high-quality SD-OCT images with a signal strength index (SSI) greater than 50 were sent for analysis. The parafoveal retinal thickness (parafoveal RT) and central foveal thickness (CFT), CT, peripapillary RNFL thickness, and macular GCC thickness measurements were performed with an RTVue-100 OCT device (Optovue Inc., Fremont, US), which had a 5 µm axial image resolution with a speed of 27,000 A-scans per second.
We preferred the ONH map protocol for examining the RNFL parameters. This protocol creates a RNFL thickness map based on measurements around a circle 3.45 mm in diameter centred on the ONH. The protocol for the GCC scan was based on examining a square grid (7 × 7 mm) on the central macula after centring 1 mm temporal to the macula. The average, superior, and inferior values displayed by the device were studied for the mean GCC and mean RNFL parameters.
Segmental divisions were recorded with the MM5 protocol of the inbuilt software, characterized by a 5 × 5 mm2 grid of 11 horizontal and 11 vertical lines with 668 A-scans and a 3 × 3 mm2 inner grid of 6 horizontal and 6 vertical lines with 400 A-scans for the retinal thickness of a 1 mm diameter CFT. The CT was measured by cross-sectioning through the foveolar centre line, characterized by an 8 mm width, with 1024 A-scans captured on the chorioretinal mode (these settings enable enhanced depth imaging along with contrast and brightness tuning). The line was rotated horizontally and vertically so that manual measurements were taken first at the central foveola and then 750 µm apart in the nasal, temporal, superior, and inferior directions with the ruler function, using a line extending from the posterior edge of the retinal pigment epithelium to the choroidoscleral junction.
The choroidal structure was analysed using the method previously described by Agrawal et al., and all collected images were processed and analysed using the open-source and publicly available ImageJ software (version 1.50a, freely available at http://imagej.nih.gov/ij/; National Institutes of Health [NIH], Bethesda, MD). According to this method, the image was first binarized using the Niblack auto-local thresholding function. This provided a clear visualization of the choroidoscleral interface while also enabling the precise selection of a region of interest, such as the total subfoveal choroidal area (TA). A fovea-centred, 1500 μm wide, nasal-to-temporal subfoveal choroidal area was manually selected using the polygon selection tool. The dark pixels representing the luminal area (LA) were selected using the colour threshold tool, and the residual light pixels were considered the stromal area (SA). The subfoveal CVI was calculated as the ratio of the LA to the TA. Manual measurements (CT and CVI) were carried out by the same experienced investigator blinded to the groups. Each measurement was repeated twice, and the mean of the two measurements was used in the analysis.
Statistical analysis Statistical analysis was conducted with software (SPSS 22.0 Version, IBM Corporation, New York, USA). Descriptive statistics were stated as the mean, standard deviation (SD), or median (Med), the interquartile range (Q1-Q3), and the frequency and ratio (%) values, where appropriate. The distribution of normality was evaluated for each parameter with the Kolmogorov-Smirnov test. Parametric (for normal distribution) or non-parametric tests were applied as appropriate. A parametric analysis of variance (ANOVA) with a post hoc Tukey test or a non-parametric Kruskal-Wallis test with a post hoc Bonferroni-corrected Mann-Whitney U test was used to analyse the independent variables. The chi-square test was used to analyse the qualitative data. Correlations of choroidal thickness measurements with parameters relevant to SC use were studied using the Spearman test.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Control Group | – | –Eyes of subjects with no history of use of any substance |
| Seronegative Synthetic Cannabinoids Group | – | –Eyes of patients declaring no present use of any substance and as verified by three consecutive negative urine toxicology tests performed two weeks apart |
| Seropositive Synthetic Cannabinoids Group | – | –Eyes of patients with positive urine toxicology tests proving present use of synthetic cannabinoids |
Who may qualify
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The judiciary-supervised probation unit of Alcohol and Substance Research, Treatment and Training Centre (AMATEM) of Department of Psychiatry, Bakirkoy Training and Research Hospital for Psychiatry, Neurology and Neurosurgery, Istanbul, Turkey
Key inclusion criteria (2 listed)
- Male patients with past synthetic cannabinoids use and
- 30 eyes of age-matched 30 male healthy control subjects
Key exclusion criteria (6 listed)
- present co-use of any substances other than synthetic cannabinoids
- chronic ocular disease, such as uveitis or glaucoma
- history of previous ocular surgery
- systemic disease, such as diabetes mellitus or hypertension
- systemic or topical drug use that may influence vascular tone, such as topical anti-glaucomatous and systemic anti-hypertensive medications
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Intraocular pressure
Time frame: All assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.
Intraocular pressure measurement by non-contact air-puff tonometer. Intraocular pressure will be reported in mmHg
Central foveal thickness
Time frame: All assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.
All measurements were obtained with the built-in software of the SD-OCT device. Central foveal thickness will be reported in µm.
Peripapillary retinal nerve fibre layer thickness
Time frame: All assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.
All measurements were obtained with the built-in software of the SD-OCT device. Peripapillary retinal nerve fibre layer thickness will be reported in µm.
Macular ganglion cell complex thickness
Time frame: All assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.
All measurements were obtained with the built-in software of the SD-OCT device. Macular Ganglion cell complex thickness will be reported in µm.
Subfoveal and perifoveal choroidal thicknesses
Time frame: All SD-OCT assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.
Choroidal imaging carried out with Spectral domain optical coherence tomography by chorioretinal mode. All choroidal thicknesses were measured with the built-in caliper function. Subfoveal and perifoveal choroidal thicknesses will be reported in µm.
Choroidal vascularity index
Time frame: All assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.
All choroidal images were exported to ImageJ software and binarized with Niblack autolocal thresholding method. After binarization, dark pixels indicate luminal area, and white pixels indicate stromal area. "Luminal area/total area(stromal+luminal area) * 100" formula will be used for choroidal vascularity index (CVI) calculation. CVI will be reported in %
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jan 2024.
- Background: PubMed 26751702Agrawal R, Salman M, Tan KA, Karampelas M, Sim DA, Keane PA, Pavesio C. Choroidal Vascularity Index (CVI)--A Novel Optical Coherence Tomography Parameter for Monitoring Patients with Panuveitis? PLoS One. 2016 Jan 11;11(1):e0146344. doi: 10.1371/journal.pone.0146344. eCollection 2016.
- Derived from this study: PubMed 39375488Kunduraci MS, Kirik F, Onur IU, Onur OS, Karsidag C, Yigit FU, Erkiran M. Ocular effects of synthetic cannabinoids: a case-control study. Eye (Lond). 2025 Jan;39(1):94-101. doi: 10.1038/s41433-024-03381-x. Epub 2024 Oct 8.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ismail Umut Onur, MD study director
Bakirkoy Dr. Sadi Konuk Educational and Research Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Synthetic Cannabinoid Abuse (Disorder) and Eye Manifestations, run by Bezmialem Vakif University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Intraocular pressure (time frame: All assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06235346, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jan 2024.